NewAmsterdam Pharma

Home
United States
Aventura, FL
NewAmsterdam Pharma

NewAmsterdam Pharma Corporation is a late-stage clinical biopharma company. Intended for US audiences Intended for US audiences only.

NewAmsterdam Pharma Corporation is a late-stage clinical biopharma company developing therapies for cardiometabolic diseases.

03/06/2026

On , we’re grateful for the 105 team members across five countries and 19 states whose dedication, insight, and heart drive our work. Together, they bring purpose to our progress in advancing science for cardiovascular disease and other lipid-related conditions.

02/16/2026

Alzheimer’s and Dementia Care Education Week is a timely reminder that understanding and managing lipids may support long-term brain health and overall well-being.

Learn more about the connection between lipids and Alzheimer’s disease: https://www.newamsterdampharma.com/lipid-related-conditions/?utm_source=fb&utm_medium=organic&utm_campaign=alzheimer’s-&dementia-care-education-week&utm_content=lipid-related-conditions

02/06/2026

On Wear Red Day, we’re shining a light on a risk that often hides in plain sight: as estrogen declines during menopause, cardiovascular risk rises.

Lifestyle changes, regular check-ins, and, when appropriate, medical intervention can help women protect their long-term heart health.

Learn more about risk factors associated with cardiovascular disease. https://www.newamsterdampharma.com/our-focus/

02/03/2026

Atherosclerosis develops quietly, long before symptoms appear. For many, it’s not just lifestyle—it’s genetics, inherited risk, and the way their blood vessels respond to the world around them.

Listen as Prof. Kausik Ray explains why caring for your blood vessels today can prevent urgent problems tomorrow.

Learn more about cardiovascular risk factors: https://bit.ly/45K5fLY

01/01/2026

Happy New Year from all of us at NewAmsterdam Pharma!

We’re excited for what 2026 has in store, particularly as we continue to advance PREVAIL, our Phase 3 cardiovascular outcomes trial. The stage is set for another year of progress!

12/17/2025

Happy holidays and best wishes for a healthy and joyful New Year from all of us at NewAmsterdam Pharma! As we look ahead to 2026, we remain committed to advancing our lead investigational asset and exploring new ways to address the global impact of cardiovascular disease.

12/02/2025

Taking charge of your heart health is a team effort. Clinical recommendations help guide prevention, screening, and treatment—while your actions, like tracking risk factors and adopting healthy habits, make the difference.

Learn more about preventing heart disease from the American Heart Association: https://www.heart.org/en/healthy-living/healthy-lifestyle/how-to-help-prevent-heart-disease-at-any-age

11/24/2025

Lp(a) isn’t as well-known as LDL-C, but high levels can sharply increase the risk of heart attacks and strokes—even in people with normal LDL. This recent Washington Post st article explores the science behind Lp(a), its genetic roots, and why it’s gaining attention among researchers and clinicians.

https://wapo.st/48vKTaV

11/17/2025

Our focus always returns to the science and the patients we serve. Company meetings like the one we hosted last month reignite our energy, sharpen our clarity, and strengthen our connection to our shared mission and each other. Because when teams align around purpose, the impact goes far beyond the room.

11/14/2025

About 1 in 9 adults worldwide are living with diabetes, and the diagnosis doubles the risk for heart disease. People with type 2 diabetes have a similar risk of cardiovascular disease as those who already have it.

This , learn more about our research: https://www.newamsterdampharma.com/lipid-related-conditions/

11/09/2025

LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk.

Learn about each of these factors: https://bit.ly/43iWOpI

10/28/2025

Even when taking statins, many ASCVD patients continue to face significant residual cardiovascular risk. Professor Stephen Nicholls highlights that while lowering LDL-C remains crucial, it’s not the only factor driving heart disease.

Address

Aventura, FL

Website

https://www.newamsterdampharma.com/

Alerts

Be the first to know and let us send you an email when NewAmsterdam Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Aventura?